IDEAS Kids
Effects of IBD Therapy During Pregnancy

Effects of IBD Therapy During Pregnancy

In pregnant women treated for inflammatory bowel diseases, infliximab and adalimumab, but not certolizumab, cross the placenta and are detected in infants up to 6 months after birth, according to the March issue of Clinical Gastroenterology and Hepatology (CGH). However, they do not appear to cause birth defects, and women who stop taking the drugs during pregnancy are able to start taking them again after delivery.

As therapeutic options for IBD increase, more patients are able to consider pregnancy. Yet it is not clear whether tumor necrosis factor (TNF) inhibitors are transferred to the fetus or cause complications during pregnancy. Two studies provide important new data about placental transfer of anti-TNF agents and their effects on the health of women and newborns.

What are the Effects of IBD Therapy During Pregnancy?

Leave a Reply